Overall, monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors, and mTOR inhibitors were more likely to accompany ILD. Here, MTOR is linked to interstitial lung disease.